Phase II study of fludarabine phosphate (NSC 312887) in patients with advanced cervical cancer. A Southwest Oncology Group study

Am J Clin Oncol. 1990 Oct;13(5):433-5. doi: 10.1097/00000421-199010000-00014.


Twenty evaluable patients with advanced cervical cancer refractory to one prior chemotherapy regimen were treated with a 5-day schedule of fludarabine phosphate. No responses were noted. The major toxicities were anemia and leukopenia. Based on this study, fludarabine phosphate does not appear to be an active agent for patients with chemotherapy refractory cervical cancer.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Anemia / chemically induced
  • Antimetabolites, Antineoplastic / adverse effects
  • Antimetabolites, Antineoplastic / therapeutic use*
  • Drug Evaluation
  • Female
  • Humans
  • Leukopenia / chemically induced
  • Middle Aged
  • United States
  • Uterine Cervical Neoplasms / drug therapy*
  • Vidarabine Phosphate / adverse effects
  • Vidarabine Phosphate / analogs & derivatives*
  • Vidarabine Phosphate / therapeutic use


  • Antimetabolites, Antineoplastic
  • Vidarabine Phosphate
  • fludarabine phosphate